JP7432598B2 - 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法 - Google Patents

重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法 Download PDF

Info

Publication number
JP7432598B2
JP7432598B2 JP2021525049A JP2021525049A JP7432598B2 JP 7432598 B2 JP7432598 B2 JP 7432598B2 JP 2021525049 A JP2021525049 A JP 2021525049A JP 2021525049 A JP2021525049 A JP 2021525049A JP 7432598 B2 JP7432598 B2 JP 7432598B2
Authority
JP
Japan
Prior art keywords
subject
diabetes
test substance
hfd
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517483A (ja
Inventor
エドルンド，ヘレナ
エリクソン，ビョルン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of JP2022517483A publication Critical patent/JP2022517483A/ja
Priority to JP2023097964A priority Critical patent/JP7755618B2/ja
Application granted granted Critical
Publication of JP7432598B2 publication Critical patent/JP7432598B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021525049A 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法 Active JP7432598B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097964A JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2018/053203 WO2020095010A1 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097964A Division JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Publications (2)

Publication Number Publication Date
JP2022517483A JP2022517483A (ja) 2022-03-09
JP7432598B2 true JP7432598B2 (ja) 2024-02-16

Family

ID=64332106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525049A Active JP7432598B2 (ja) 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法
JP2023097964A Active JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023097964A Active JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Country Status (5)

Country Link
US (1) US20220023269A1 (https=)
JP (2) JP7432598B2 (https=)
AU (2) AU2018448511B2 (https=)
CA (1) CA3118629A1 (https=)
WO (1) WO2020095010A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910092D0 (en) * 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507530A (ja) 2008-10-29 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体
JP2012532854A (ja) 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
WO2017119515A1 (en) 2016-01-05 2017-07-13 Nrl Pharma, Inc. Ascochlorin derivative and use thereof as ampk activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
JP2007517025A (ja) 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
MY182801A (en) 2013-09-26 2021-02-05 Energenesis Biomedical Co Ltd Compound for activating ampk and uses thereof
KR101986983B1 (ko) 2015-01-07 2019-06-07 창저우 더저 메디컬 사이언스 컴퍼니.,리미티드 망기페린-6-ｏ-베르베린염 수화물 및 그 제조방법과 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507530A (ja) 2008-10-29 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病剤である新規な環状ベンズイミダゾール誘導体
JP2012532854A (ja) 2009-07-08 2012-12-20 バルティック バイオ アーベー 医薬として有用な化合物
WO2017119515A1 (en) 2016-01-05 2017-07-13 Nrl Pharma, Inc. Ascochlorin derivative and use thereof as ampk activator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diabetes，2016年，Vol.65，p.2784-2794
EU Clinical Trials Register, EudraCT Number:2016-002183-13，2016年

Also Published As

Publication number Publication date
JP7755618B2 (ja) 2025-10-16
US20220023269A1 (en) 2022-01-27
JP2022517483A (ja) 2022-03-09
WO2020095010A1 (en) 2020-05-14
CA3118629A1 (en) 2020-05-14
AU2025238101A1 (en) 2025-11-13
JP2023116697A (ja) 2023-08-22
AU2018448511A1 (en) 2021-05-27
AU2018448511B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
JP7755618B2 (ja) 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法
Nesti et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Godinho et al. The place of dipeptidyl peptidase‐4 inhibitors in type 2 diabetes therapeutics: A “me too” or “the special one” antidiabetic class?
Chen et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
Koga et al. MELAS and L-arginine therapy
Townsend et al. AMPK mediates energetic stress‐induced liver GDF15
Angebault et al. Metformin reverses the enhanced myocardial SR/ER–mitochondria interaction and impaired complex I-driven respiration in dystrophin-deficient mice
Oidor-Chan et al. Fenofibrate plus metformin produces cardioprotection in a type 2 diabetes and acute myocardial infarction model
US8299083B2 (en) PDE5 inhibitor compositions and methods for treating cardiac indications
Raghunathan et al. Evaluation of buspirone on streptozotocin induced type 1 diabetes and its associated complications
Rochester et al. Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient
Sosa et al. Impact of hyperuricemia and urate-lowering agents on cardiovascular diseases
Deng et al. Hyperhomocysteinemia promotes cardiac hypertrophy in hypertension
Nishiyama et al. Protective effects of imeglimin and metformin combination therapy on β-cells in db/db male mice
Weng et al. PER2 regulates reactive oxygen species production in the circadian susceptibility to ischemia/reperfusion injury in the heart
Zuo et al. Activation of the PP2A catalytic subunit by ivabradine attenuates the development of diabetic cardiomyopathy
Barragán-Bonilla et al. Combined administration of streptozotocin and sucrose accelerates the appearance of type 2 diabetes symptoms in rats
Cao et al. Low dose of folic acid can ameliorate hyperhomocysteinemia-induced cardiac fibrosis and diastolic dysfunction in spontaneously hypertensive rats
JP7613693B2 (ja) Ｐｐ２ａアンカリングの阻害による心疾患の処置
Liu et al. Narrative literature review of antidiabetic drugs’ effect on hyperuricemia: elaborating actual data and mechanisms
JP2012510511A (ja) レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用
Wang et al. Effect of adenosine monophosphate‐activated protein kinase–p53–Krüppel‐like factor 2a pathway in hyperglycemia‐induced cardiac remodeling in adult zebrafish
Busija et al. Adverse effects of reactive oxygen species on vascular reactivity in insulin resistance
JP7645244B2 (ja) 代謝性疾患と闘うために使用される組成物およびその組成物の使用
Zhao et al. Tolerability, safety, pharmacokinetics, and pharmacodynamics of SY-004, a glucokinase activator, in healthy Chinese adults: a randomized, phase Ia, single-ascending dose study

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20210730

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20210730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432598

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150